Skip to main content
TRUMF logo

Terumo Corporation (TRUMF) Stock Price & Analysis

Terumo Corporation (TRUMF) — price $15.68 (0.00%), as of the Nov 19, 2026 trading session; market cap $23.1B. Expected results Feb 10, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$15.68 $0.00 (0.00%) Market Cap $23.1B

Terumo Corporation · TRUMF · Healthcare · Medical - Devices

Terumo Corporation is a global medical technology company specializing in the development, manufacturing, and distribution of a wide array of healthcare products and equipment.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • STE · STERIS plc · 87 /100
  • ZBH · Zimmer Biomet Holdings, Inc. · 79 /100
  • PHG · Koninklijke Philips N.V. · 78 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$15.68
Change on the day0.00%
52-week range$11.49–$17.35
Market capitalisation$23.1B
Price / earnings (trailing)33.04
Shares traded on the day100
Beta (volatility vs the S&P 500)0.23
Dividends per share (last 12 months)$0.21
Dividend yield (last 12 months)1.33%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $12, high $17, latest $16. 4 reported quarters marked, 2 above and 2 below the recorded estimate. $17 $12 high $17 Feb 13, 2026 · Earnings results · reported below the recorded estimate · close $141May 15, 2026 · Earnings results · reported above the recorded estimate · close $122Aug 7, 2026 · Earnings results · reported above the recorded estimate · close $143Nov 12, 2026 · Earnings results · reported below the recorded estimate · close $154 Oct 17, 2025 Nov 19, 2026 · $16 $16Oct 17, 2025$15Oct 31, 2025$17Nov 14, 2025$17Nov 28, 2025$15Dec 12, 2025$15Dec 26, 2025$15Jan 9, 2026$14Jan 23, 2026$14Feb 6, 2026$13Feb 20, 2026$12Mar 6, 2026$12Mar 20, 2026$12Apr 2, 2026$13Apr 17, 2026$13May 1, 2026$12May 15, 2026$15May 29, 2026$15Jun 12, 2026$13Jun 26, 2026$14Jul 10, 2026$13Jul 24, 2026$14Aug 7, 2026$16Aug 21, 2026$14Sep 4, 2026$14Sep 18, 2026$14Oct 2, 2026$14Oct 16, 2026$15Oct 30, 2026$15Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

Dated events ahead, in order, not to scaleDec 2, 2026, Dividend payment date; Feb 10, 2027, Next results due. Spacing is order only and carries no duration.Nov 19, 20261Dec 2, 20262Feb 10, 2027
  1. Dividend payment dateCompany record
  2. Next results dueProvider estimate
How to read these dates

Events are in date order; the spacing is not a duration scale. Estimated dates can change.

What to watch next

Other perspectives

Council score for Terumo (TRUMF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 7, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Neutral
Debt/Equity Moderate
ROE Neutral
Gross Margin Moderate

Read on: Sep 3, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 3, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Terumo (TRUMF), and what does it report?

Short answer · as of

Terumo Corporation is a global medical technology company specializing in the development, manufacturing, and distribution of a wide array of healthcare products and equipment. Healthcare / Medical Devices Headquarters: 2-44-1, Hatagaya, Tokyo, TY, 151-0072, JP. It employs 31,185 people and is led by Hikaru Samejima. In Q1 FY2027 it reported revenue of ¥309.56B and net income of ¥69.92B. The market values it at $23.1B.

2 · Latest results

What do the latest results show for Terumo (TRUMF)?

Short answer · as of

The most recent reported quarter, Q1 FY2027, carried revenue of ¥309.56B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.99B Nov 12, 2026
Latest report · revenue estimate
$1.95B Nov 12, 2026
Latest report · revenue vs estimate
Above estimate Nov 12, 2026
Latest report · EPS vs estimate
Below estimate Nov 12, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 12, 2026$1.99B$1.95B−$0.0681−$0.0085
Aug 7, 2026$1.92B$1.82B$0.2936$0.1592
May 15, 2026$1.89B$1.83B$0.1125$0.0945
Feb 13, 2026$1.89B$1.83B$0.1413$0.1440
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2027¥309.56B¥69.92B¥46.82 (diluted)
Q4 FY2026¥302.21B¥26.53B¥17.58 (diluted)
Q3 FY2026¥296.89B¥32.68B¥21.96 (diluted)
Q2 FY2026¥278.89B¥35.55B¥24.00 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Terumo (TRUMF)?

Short answer · as of

The distress and quality screens read Altman Z 5.32 · Piotroski F 5. Trailing ratios: ROE 7.1% · ROA 5.1% · current ratio 2.87 · earnings yield 3.0% · free-cash-flow yield 5.3%.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
  • Rich valuation — a P/E of 33.04 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Terumo (TRUMF)?

Short answer · as of

The next earnings report is expected on Feb 10, 2027.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held TRUMF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported TRUMF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Terumo (TRUMF)?

Read these with our analysis →

TRUMF Healthcare Stock FAQ

These answers are editorial: 1 of these 8 answers is drawn from the TRUMF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is TRUMF a good stock to buy?

Stock Expert AI does not rate TRUMF buy, sell or hold. Terumo Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the TRUMF stock price today?

The last price recorded for Terumo Corporation (TRUMF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

How does Terumo Corporation maintain its competitive edge in the medical technology market?

Terumo Corporation maintains its competitive edge through several key strategies. Firstly, its extensive and diversified product portfolio across critical healthcare areas reduces reliance on any single market segment and caters to a wide range of medical needs.

What are the key factors to evaluate for TRUMF?

Evaluate TRUMF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. The global burden of stroke and cerebral aneurysms remains high, driving continuous demand for more effective and less invasive treatment options. Not financial advice.

How frequently does TRUMF data refresh on this page?

TRUMF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven TRUMF's recent stock price performance?

Terumo Corporation (TRUMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across critical healthcare segments (cardiovascular, general medical, blood/cell technologies). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider TRUMF overvalued or undervalued right now?

The trailing P/E of Terumo Corporation (TRUMF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research TRUMF before investing?

Before investing in Terumo Corporation (TRUMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 41 figures on this page — 33 from Financial Modeling Prep (FMP), 3 with no recorded source, 4 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.